Navigation Links
SCOLR Pharma Welcomes Clem Calabrese as Director of Field Sales

BELLEVUE, Wash., May 1, 2012 /PRNewswire/ -- SCOLR Pharma, Inc. (OTCQB: SCLR) announced today that effective May 1, 2012 Clem Calabrese will be joining the SCOLR team as Director of Field Sales to lead our aggressive field sales & marketing activities.  Clem brings a wealth of field sales experience to SCOLR and will be primarily responsible for working with our existing sales staff, the Emerson Group and our retail customers in order to ensure we aggressively grow our sales while providing the utmost in customer service.

Clem brings over 35 years of Branded and Store Brand Sales & Marketing experience with Major Consumer Products Companies.

Stephen Turner, President and CEO of SCOLR, said: "We are excited to have Clem join the SCOLR team.  He is an impressive individual and will most assuredly provide us with additional sales opportunities as we continue to grow our consumer products sales.  The depth of his relationships and contacts within the industry will enable SCOLR to continue the momentum created with our CDT® Controlled Release Technology with retailers."

About SCOLR Pharma:

Based in Bellevue, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company focused on applying its formulation expertise and patented CDT® platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products. Its CDT® drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425-368-1050 or visit

Forward looking statements:                                              

Any statements made in this press release that relate to future plans, events or performance are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These forward looking statements include statements regarding SCOLR's partners development of drug formulations, the results of a bioequivalence trials, anticipated future plans related to approval of drug formulations by the Food and Drug Administration, and the development and marketing of any drug formulations.  Factors that could cause these forward-looking statements to differ from actual results include adverse regulatory determinations related to trials, competitive factors related to drug products, economic factors including partner's ability to finance the development and commercialization of any product, and other risks and uncertainties discussed in the company's periodic reports on Form 10-K and 10-Q and other filings with the Securities and Exchange Commission.  SCOLR Pharma, Inc. undertakes no obligation to update or revise any forward-looking statements.

Investor Relations:                                             
SCOLR Pharma, Inc.                                            

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SCOLR Pharma, Inc. Provides Product Information on Website
2. SCOLR Pharma, Inc. Launches Cutting Edge Nutritional Products at Major Retailers in 2012
3. SCOLR Pharmas Partner to Commence Bioequivalence Study of Ondansetron
4. SCOLR Pharma, Inc. Announces Initial Shipments of its Nutritional Products
5. SCOLR Pharma, Inc. Announces Second Quarter 2011 Financial Results
6. SCOLR Pharma, Inc. First Quarter 2011 Financial Results
7. SCOLR Pharma, Inc. to Present at Taglich Brothers 8th Annual Small Cap Equity Conference
8. SCOLR Pharma, Inc. Reports 2010 Financial Results, Provides Updates on Advances in Nutritionals, OTC Drugs
9. SCOLR Pharma, Inc. Receives Deficiency Letter from FDA on Pseudoephedrine Application
10. SCOLR Pharma, Inc. Retains Nicholas Hall & Company
11. SCOLR Pharma, Inc. Common Stock to Begin Trading on OTC Bulletin Board and OTCQB Stock Market on January 13, 2011
Post Your Comments:
(Date:11/26/2015)... , 26 november 2015 ... kondigt de geplande investering aan van ten ... de laboratoria en het mondiale hoofdkantoor in ... uitbreiding zal resulteren in extra kantoorruimte en ... aan de groeiende behoeften van de farmaceutische ...
(Date:11/26/2015)... UTRECHT , Nederland, November 26, 2015 ... --> Een nieuwe aanpak combineert ... van gevorderde kanker. ... -->      (Photo: ... van het Leids Universitair Medisch Centrum (LUMC) ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ) ... Pacemaker Market Outlook to 2019 - Rise in Cardiac Disorders ... report to their offering. Boston ... Boston scientific and others. --> ... Biotronik, Boston scientific and others. ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... ... sauna parts and accessories. , Sauna accessories help improve the bather experience in ... personality. From basic styles for the purist looking for simplicity in design to ...
(Date:11/25/2015)... ... 26, 2015 , ... Ministers, senior government and UN agencies, ... Centres of Excellence, and public R&D institutions, civil societies and other partners gathered ... 5th African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, ... Two Organizations, One Beat ” campaign. The partnership between the two groups began in ... in MAP International’s cause. , MAP International was founded in 1954 and is an ...
(Date:11/25/2015)... FL (PRWEB) , ... November 25, 2015 , ... ... center, is encouraging people across the country to celebrate their sobriety and show ... people to post “before and after” photos this Thanksgiving with the hashtag #FacesOfGratitude ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... On November ... training center for the Narconon network, announced the release of a new cutting edge ... the Narconon organization has been working with drug- and alcohol-addicted individuals with the purpose ...
Breaking Medicine News(10 mins):